Sample Record for Search: Research Status of Drugs
Drug: 18-methoxycoronaridine; (-)-18-methoxycoronaridine
Latest Information:
2 December 2002: Albany Medical College (USA) and the University of Vermont (USA) presented preclinical data on 18-methoxycoronaridine (18-MC) at the 32nd Annual Meeting of the Society for Neuroscience, 2-7 November 2002, Orlando, USA. 18-MC is the lead compound in a series of congeners of ibogaine, being developed for the potential treatment of multiple forms of drug abuse. In animal models of addiction, 18-MC reduced self-administration of morphine, cocaine, methamphetamine, nicotine and ethanol but did not evoke the negative behavioral side effects seen with ibogaine. 18-MC bound potently to alpha3beta4 nicotinic acetylcholine receptors but had no effect on NR1/2B NMDA receptors at concentrations of up to 50 mcM.
Development History:
Commercial Summary:
Albany Medical College (USA) and University of Vermont (USA) are co-developing a series of ibogaine congeners as potential therapies for drug abuse. The lead compound, 18-methoxycoronaridine (18-MC), is undergoing preclinical studies in the USA. 18-MC is thought to act via inhibition at alpha3beta4 nicotinic acetylcholine receptors. A licensing agreement has been signed with a group of investors, who under the agreement, are to start a new company within the next two years to develop this compound (Albany Medical College; University of Vermont, NOV 2002).
Scientific Summary:
18-MC binds to alpha3beta4 nicotinic acetylcholine receptors with an IC50 of less than 1 mcM and shows no effect on NR1/2 NMDA receptors at concentrations of up to 50 mcM. The amount of reduction in morphine and methamphetamine self-administration is positively correlated with the compounds affinity for the alpha3beta4 receptor in an animal model of drug addiction (32nd Neuroscience, Abs 901.1, NOV 2002).
Patent Summary:
Product: WO 97/05869 1997, priority US 002048 1995, designating 20 states. One equivalent identified.
Source: R&D Focus, December 16, 2002
IMS R&D Focus
© 2003 IMS Health & Affiliates. All rights reserved.
Dialog® File Number 445 Accession Number 2019419
